StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform for Precision Oncology
Oversubscribed round expand global reach, and unlock multi‑billion‑euro cancer diagnostics market
Advertisement
StratifAI, the AI biomarker company for precision oncology, has secured €12.5 million in an oversubscribed funding round. The funding will accelerate the clinical validation of its multimodal AI biomarker discovery platform, Polaris™. The round was led by Picus Capital, with co-lead Alven, alongside Heliad, Rubin Ritter, Lars Langusch, and Jens Begemann. Existing backers Debiopharm, Arve Capital, Christoph Haarburger also joined, deepening their commitment to StratifAI’s vision.
Despite advances in cancer care, biomarker discovery remains slow, costly, and limited in scope, leaving vast opportunities untapped. StratifAI’s fully digital, AI‑driven approach is designed to accelerate biomarker discovery, reduce costs, addressing one of the largest unmet needs in oncology.
Redefining biomarker discovery
What once demanded costly, specialized techniques, Polaris™ now achieves from routine histology – delivering spatial insights into tumors at a scale not seen before. By integrating H&E histology with RNASeq gene expression data, the platform instantly links spatial tumor signals to patient outcomes: eliminating additional testing, reducing costs, and revealing new prognostic and predictive insights. The company sources tumor samples, generates high-quality data, and expands a growing portfolio of spatial biomarkers while building a comprehensive multimodal reference dataset. StratifAI’s first product, Polaris™ Breast, is designed to assess the risk of breast cancer recurrence.
First clinical application: Polaris™ Breast
StratifAI's first product Polaris™ Breast was developed to assess the risk of recurrence in breast cancer. The newly raised capital accelerates clinical validation and advances the approval process in Europe and the US. StratifAI is expanding its collaborations with leading oncology centers and pharmaceutical companies to generate extensive clinical evidence that will pave the way for guidelines and drive application in everyday clinical practice.
"Artificial intelligence can gain insights from human data - such as high-resolution cell scans - that were previously not possible. This opens up enormous potential for groundbreaking advances in healthcare. The application in the field of breast cancer is already extremely promising, but it is only the beginning - especially if we expand the application to data from other medical fields," emphasized Robin Godenrath, Founding Partner & Managing Director at Picus Capital.
"The increasing digitalization of histology will create an immense volume of data. This will create completely new opportunities for medical breakthroughs and a deeper understanding of diseases. StratifAI is exactly at this point - with cutting-edge technology, strong partners and a founding team that shows a clear vision and great determination," says Maria Tahri, Partner at Alven.
StratifAI is currently strengthening its team and international presence to ensure that the platform reflects the diversity of patient groups. As a result, StratifAI is ideally positioned to lead the development of the next generation of cancer biomarkers. The company's digital, AI-powered approach has the potential to unlock one of the largest untapped markets in cancer diagnostics to date - by fundamentally redefining the way biomarkers are developed and delivered.
"This investment will enable us to create a scalable regulatory framework for the development of clinically robust AI diagnostics, expand our ecosystem with diverse, high-quality clinical data and provide better tests to support treatment decisions," said Omar El Nahhas, CEO and co-founder of StratifAI. "With the support of our investors, who bring extensive expertise in rapid implementation and global growth, we are setting a new standard for faster and more accessible clinical decision support. By prioritizing biodiversity in our data, we are developing solutions with global applicability and positioning StratifAI at the forefront of the market.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
